Keval Chandarana1, Rachel Batterham. 1. Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London, WC1E 6JJ, UK.
Abstract
PURPOSE OF REVIEW: This review discusses recent studies examining the effects of peptide YY on energy homeostasis, highlights the emerging hedonic effects of peptide YY and evaluates the therapeutic potential of the peptide YY system. RECENT FINDINGS: A role for exogenous PYY3-36 as an anorectic agent in obese humans and rodents has been established and weight loss effects demonstrated in obese rodents. New lines of evidence support a role for endogenous peptide YY in regulating energy homeostasis. The NPY-Y2 receptor mediates the anorectic actions of PYY3-36 with rodent studies implicating the hypothalamus, vagus and brainstem as key target sites. Functional imaging in humans has confirmed that PYY3-36 activates brainstem and hypothalamic regions. The greatest effects, however, were observed within the orbitofrontal cortex, a brain region involved in reward processing. Further evidence for a hedonic role for PYY3-36 is supported by rodent studies showing that PYY3-36 decreases the motivation to seek high-fat food. Rodent studies using selective Y2 agonists and strategies combining PYY3-36/Y2 agonists with other anorectic agents have revealed increased anorectic and weight-reducing effects. SUMMARY: Peptide YY plays a role in the integrative regulation of metabolism. The emerging hedonic effects of peptide YY together with the weight-reducing effects observed in obese rodents suggest that targeting the peptide YY system may offer a therapeutic strategy for obesity.
PURPOSE OF REVIEW: This review discusses recent studies examining the effects of peptide YY on energy homeostasis, highlights the emerging hedonic effects of peptide YY and evaluates the therapeutic potential of the peptide YY system. RECENT FINDINGS: A role for exogenous PYY3-36 as an anorectic agent in obese humans and rodents has been established and weight loss effects demonstrated in obese rodents. New lines of evidence support a role for endogenous peptide YY in regulating energy homeostasis. The NPY-Y2 receptor mediates the anorectic actions of PYY3-36 with rodent studies implicating the hypothalamus, vagus and brainstem as key target sites. Functional imaging in humans has confirmed that PYY3-36 activates brainstem and hypothalamic regions. The greatest effects, however, were observed within the orbitofrontal cortex, a brain region involved in reward processing. Further evidence for a hedonic role for PYY3-36 is supported by rodent studies showing that PYY3-36 decreases the motivation to seek high-fat food. Rodent studies using selective Y2 agonists and strategies combining PYY3-36/Y2 agonists with other anorectic agents have revealed increased anorectic and weight-reducing effects. SUMMARY: Peptide YY plays a role in the integrative regulation of metabolism. The emerging hedonic effects of peptide YY together with the weight-reducing effects observed in obese rodents suggest that targeting the peptide YY system may offer a therapeutic strategy for obesity.
Authors: Laura A Berner; Tiffany A Brown; Jason M Lavender; Emily Lopez; Christina E Wierenga; Walter H Kaye Journal: Mol Cell Endocrinol Date: 2018-11-02 Impact factor: 4.102
Authors: Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt Journal: Neurosci Biobehav Rev Date: 2021-10-29 Impact factor: 8.989
Authors: Yafang Zhang; Suditi Rahematpura; Kael H Ragnini; Amanda Moreno; Kamryn S Stecyk; Michelle W Kahng; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt Journal: Neuropharmacology Date: 2021-05-11 Impact factor: 5.273